SUBSCRIBE
SUBSCRIBE

Preclinical

Drug Development
Chocolate Treats Migraines, Mississippi State University Study
September 18, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Moths As Good As Mice For Many Drug Tests, National University Of Ireland Study
September 8, 2009
 · 
1 min read
Bookmark and Share
Drug Development
EU Chemicals Law “Spells Surge In Animal Testing”, Bloomberg School of Public Health Study
August 27, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Multiple Sclerosis Successfully Reversed In Mice: New Immune-suppressing Treatment Forces The Disease Into Remission, Jewish General Hospital Lady Davis Institute for Medical Research And McGill University Study
August 12, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Scientists Slowed Growth Of Ovarian Tumors In Mice Using Nanoparticles To Deliver Suicide Genes, Lankenau Institute for Medical Research And Massachusetts Institute of Technology (MIT) Study
July 30, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Roche Drug Blocks Common Cancer Pathway In Mice
July 15, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Anthrax Drug Could Thwart Terrorists, Human Genome Sciences, Inc.'s Researchers Say
July 9, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Cortex Pharmaceuticals, Inc. Release: Novel Compounds May Help Protect Against Respiratory Depression
June 23, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Preclinical Work Shows How One Gene Causes Severe Mental Retardation, Duke University Medical Center And University of North Carolina Study
May 11, 2009
 · 
1 min read
Drug Development
Missing Enzyme Conveys Major Heart Protection In Pre-clinical Work, Duke University Medical Center Study
April 6, 2009
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology
December 23, 2025
 · 
3 min read
Press Releases
Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026
December 22, 2025
 · 
3 min read
Press Releases
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
December 18, 2025
 · 
14 min read
Press Releases
Singlera Genomics announces research collaboration with the University of Pittsburgh to advance pancreatic cancer early detection
December 18, 2025
 · 
2 min read
Press Releases
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
December 18, 2025
 · 
4 min read
Press Releases
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World’s First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
December 16, 2025
 · 
4 min read
Press Releases
Feinstein Institutes’ Researchers Develop Promising Therapeutic for Sepsis-Induced Acute Lung Injury
December 16, 2025
 · 
4 min read
Press Releases
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
December 16, 2025
 · 
6 min read
Press Releases
Atelerix Enters Agreement with Cherry Biotech to Integrate Non-cryogenic Transport Solutions With Advanced Organoid Models
December 15, 2025
 · 
2 min read
Press Releases
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
December 12, 2025
 · 
5 min read
Press Releases
Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).
December 12, 2025
 · 
3 min read
Press Releases
NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025
December 12, 2025
 · 
3 min read
Press Releases
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
December 12, 2025
 · 
6 min read
Press Releases
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
December 11, 2025
 · 
5 min read
Press Releases
MED Institute and Sus Clinicals Announce Strategic Collaboration to Advance Preclinical Testing for Medical Product Innovation
December 11, 2025
 · 
2 min read
Press Releases
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
December 11, 2025
 · 
7 min read
Press Releases
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
December 10, 2025
 · 
4 min read
Press Releases
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
December 10, 2025
 · 
7 min read
Press Releases
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
December 10, 2025
 · 
8 min read
Press Releases
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
December 10, 2025
 · 
2 min read
Load More